Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2122805 | 0.88 | CYP19A1 (0.51) | CYP19A1CACNA1BKMT2AF2RL3IRAK4 | |
| SCHEMBL17199149 | 0.86 | CYP19A1 (0.49) | CYP19A1KMT2ATLR2TLR1 | |
| SCHEMBL31735946 | 0.85 | CYP19A1 (0.51) | CYP19A1KMT2AGAA | |
| SCHEMBL2123821 | 0.85 | CYP19A1 (0.67) | CYP19A1KMT2AF2RL3IRAK4GAA | |
| SCHEMBL30943220 | 0.85 | CYP19A1 (0.67) | CYP19A1KMT2AF2RL3IRAK4GAA | |
| SCHEMBL17199296 | 0.83 | CYP19A1 (0.70) | CYP19A1TLR2TLR1 | |
| SCHEMBL18470555 | 0.82 | CACNA1B (0.51) | CACNA1BPTGER4CNR2GAA | |
| SCHEMBL17199131 | 0.81 | CACNA1B (0.47) | CACNA1BPTGER4CNR2 | |
| SCHEMBL31735617 | 0.78 | KMT2A (0.49) | CYP19A1KMT2AF2RL3IRAK4GNRHR | |
| SCHEMBL18523466 | 0.77 | CYP19A1 (0.61) | CYP19A1KMT2ATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| WO-2015158204-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | 上海恒瑞医药有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | PTGES, PTGS1, PTGIS | CYP19A1 276/4885CACNA1B 3401/4885KMT2A 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.